ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biomarkers"

  • Abstract Number: 1723 • 2017 ACR/ARHP Annual Meeting

    Nuclear Magnetic Resonance Based Metabolomics Study Identifies Highly Discriminatory Metabolites in 87 Systemic Sclerosis Patients

    Sakir Ahmed1, Mohit Kumar Rai1, Durgesh Dubey2, Atul Rawat3, Dinesh Kumar3, Durga Prasanna Misra1 and Vikas Agarwal1, 1Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Centre for Biomedical Research, PhD Student, Lucknow, India, 3Centre for Biomedical Research, Lucknow, India

    Nuclear Magnetic Resonance based Metabolomics Study Identifies Highly Discriminatory Metabolites in 87 Systemic Sclerosis Patients Background/Purpose: Proton based Nuclear Magnetic Resonance (1H NMR) can identify…
  • Abstract Number: 2363 • 2017 ACR/ARHP Annual Meeting

    Does Galectin-3 Have Utility As a Biomarker of Subclinical Cardiovascular Disease in RA Patients Independently of RA Disease Activity?

    Amanda Nussdorf1, Isabelle Amigues2 and Joan Bathon3, 1Columbia University Medical Center, New York, NY, 2Division of Rheumatology, Columbia University Medical Center, New York, NY, 3Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY

    Background/Purpose: Galectin-3 is a beta-galactoside-binding lectin and is a marker of cardiovascular disease (CVD) in the general population. However, galectin-3 level is also elevated in…
  • Abstract Number: 94 • 2017 Pediatric Rheumatology Symposium

    Effects of Age and Gender on Reference Levels of Biomarkers Comprising the Pediatric Renal Activity Index for Lupus Nephritis (p-RAIL)

    Michael Bennett1, Qing Ma2, Jun Ying3, Prasad Devarajan1 and Hermine Brunner4, 1Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Dept of Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH, 4Rheumatology, PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose:  Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease that disproportionately effects women and children of minorities. Renal Involvement (lupus nephritis, or LN) with…
  • Abstract Number: 9 • 2017 Pediatric Rheumatology Symposium

    Biologically-Based Approach for Classifying Chronic Childhood Arthritis

    Elham Rezaei1, Daniel Hogan2, Brett Trost2, Anthony Kusalik2, Susanne Benseler3, Gilles Boire4, David A. Cabral5, Bonnie Cameron6, Sarah Campillo7, Gaëlle Chédeville8, Paul Dancey9, Ciarán M. Duffy10, Karen N Watanabe Duffy11, Janet Ellsworth12, Simon Eng13, Brian M. Feldman14, John Gordon2, Jaime Guzman15, Kristin Houghton16, Adam Huber17, Quaid Morris13, Bianca Lang18, Deborah M. Levy19, Loren Matheson20, Kiem Oen21, Ross Petty22, Suzanne Ramsey23, Johannes Roth24, Dax Rumsey25, Claire Saint-Cyr26, Rayfel Schneider27, Rosie Scuccimarri28, Earl Silverman19, Lynn R. Spiegel29, Elizabeth Stringer18, Shirley M.L. Tse30, Lori Tucker31, Rae S.M. Yeung32 and Alan Rosenberg1, 1Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, 2University of Saskatchewan, Saskatoon, SK, Canada, 3Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, 4Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, 5Pediatrics/Rm K4-121, BC Children's Hospital, Vancouver, BC, Canada, 6The Hospital for Sick Children, Toronto, ON, Canada, 7Montreal Children's Hospital, Montreal, QC, Canada, 8Rheumatology, McGill University, Montreal, QC, Canada, 9Pediatrics, Janeway Children's Hospital, St. John's, NL, Canada, 10Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, 11Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, 12University of Alberta, Edmonton, AB, Canada, 13University of Toronto, Toronto, ON, Canada, 14Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 15Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, 16Rheumatology/Pediatrics, British Columbia Childrens Hos, Vancouver, BC, Canada, 17IWK Health Centre, Halifax, NS, Canada, 18Dalhousie University, Halifax, NS, Canada, 19Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 20University of Saskatchewan, Ottawa, ON, Canada, 21University of Manitoba, Winnipeg, MB, Canada, 22Pediatric Rheumatology, Division of Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, 23Pediatric Rheumatology, IWK Health Centre, Halifax, NS, Canada, 24Pediatric Rheumatology, Children's Hospital Eastern On, Ottawa, ON, Canada, 25Stollery Children's Hospital, Edmonton, AB, Canada, 26Pediatrics, CHU Sainte-Justine, Montreal, QC, Canada, 27Division of Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, 28Division of Pediatric Rheumatology, Montreal Children's Hospital/McGill University Health Centre, Montreal, QC, Canada, 29Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, 30Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 31Pediatric Rheum/Rm K4-120, BC Childrens Hospital, Vancouver, BC, Canada, 32Paediatrics, Immunology and Medical Science, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) comprises a heterogeneous group of conditions that share chronic arthritis as a common characteristic. International uniformity in classifying JIA, based…
  • Abstract Number: 57 • 2017 Pediatric Rheumatology Symposium

    Quantification of Dynamic MRI examinations in Juvenile Idiopathic Arthritis

    Nikolay Tzaribachev1, Romiesa Hagoug2, Polymnia Louka3, Joyee Islam3, Mark Hinton3, Olga Kubassova4 and Mikael Boesen5, 1PRI - Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, 2Imaging, Image Analysis Group, London, United Kingdom, 3Image Analysis Group, London, United Kingdom, 4Image Analysis Group, Image Analysis Group, London, England, 5Radiology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Frederiskberg, Denmark

    Background/Purpose: In chronic inflammatory conditions, the need for a more objective measurement of disease activity has been identified, where dynamic contrast enhanced (DCE) MRI as…
  • Abstract Number: 32 • 2017 Pediatric Rheumatology Symposium

    High Mobility Group Box 1 Protein in Children with Kawasaki Disease and Systemic Juvenile Idiopathic Arthritis

    Hon Yan Ng1, Stefan Slomp2, Tracy Wilson-Gerwing3, Joan Dietz4, Abid Lodhi5, Tanya Holt6 and Alan Rosenberg3, 1Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, 2Pediatrics, Emergency Medicine, University of Alberta, Edmonton, AB, Canada, 3Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, 4University of Saskatchewan, Saskatoon, SK, Canada, 5Regina Qu'appelle Health Region, Regina, SK, Canada, 6University of Saskatchewan, Sasktoon, SK, Canada

    Background/Purpose: High Mobility Group Box 1 Protein (HMGB1) is a nuclear protein that stabilizes DNA and modulates gene expression.  In sepsis and in certain other…
  • Abstract Number: 31 • 2017 Pediatric Rheumatology Symposium

    Predicting therapy response to IL-1 blockade in systemic JIA: a biomarker search

    Nienke M. ter Haar1, Rianne C. Scholman1, Wilco de Jager2, Nadia Ryter3, Ariane de Ganck4, Dirk Foell5, Sytze de Roock6 and Bas Vastert7, 1Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Dept Immunology, UMC Utrecht, Utrecht, Netherlands, 3BÜHLMANN Laboratories AG, Basel, Switzerland, 4Biogazelle NV, Zwijnaarde, Belgium, 5Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, 6Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 7Division of Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Systemic onset juvenile idiopathic arthritis (sJIA) is an autoinflammatory disease, characterized by fever, rash and arthritis. The IL-1 and IL-6 pathway are crucial in…
  • Abstract Number: 143 • 2017 Pediatric Rheumatology Symposium

    Influence of Age and Sex on Collagen-Induced Arthritis

    Tracy Wilson-Gerwing1, Arash Panahifar2, David M.L. Cooper2 and Alan Rosenberg1, 1Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, 2Anatomy and Cell Biology, University of Saskatchewan, Saskatoon, SK, Canada

    Background/Purpose: Age and sex differences are found in certain subsets of juvenile idiopathic arthritis (JIA). Collagen Induced Arthritis (CIA) in rodents has utility in assessing…
  • Abstract Number: 129 • 2017 Pediatric Rheumatology Symposium

    Cell-bound Complement Activation Products Correlate with Disease Activity in Childhood-onset Systemic Lupus Erythematosus

    Joyce Hui-Yuen1, Derren Barken2, John Conklin3, Tyler O'Malley4, Andrew Eichenfield5, Amy Starr6, Lisa F. Imundo7, Thierry Dervieux4 and Anca Askanase8, 1Cohen Children's Medical Center of New York, Lake Success, NY, 2Exagen Diagnostics, Vista, CA, 31261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, 4Research and Development, Exagen Diagnostics, Vista, CA, 5Columbia University Medical Center, New York, NY, 6Pediatric Rheumatology, Columbia University Medical Center, New York, NY, 7Pediatrics, Columbia University Medical Center, New York, NY, 8Rheumatology, Columbia University Medical Center, New York, NY

    Background/Purpose: Elevated levels of cell-bound complement activation products (C4d deposition on erythrocytes [EC4d] and B lymphocytes [BC4d], CB-CAPs) have been demonstrated to be sensitive and…
  • Abstract Number: 130 • 2017 Pediatric Rheumatology Symposium

    Validation of MRP8/14 serum levels as biomarker for the diagnosis of systemic juvenile idiopathic arthritis in fever of unknown origin

    Dirk Holzinger1, Carolin Pretzer2, Maria Miranda-Garcia2,3, Hans Huppertz4, Gerd Horneff5, Johannes Peter Haas6, Gerd Ganser7, Jasmin B. Kuemmerle-Deschner8, Michael Frosch9, Johannes Roth10 and Dirk Foell2, 1Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, 2Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, 3Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Institute, Langen, Germany, 4Prof Hess Children’s Hospital Bremen, Bremen, Germany, 5Department of Pediatrics, Asklepios Clinics St. Augustin, Sankt Augustin, Germany, 6Centre for Pediatric Rheumatology Garmisch-Partenkirchen, Garmisch-Partenkirchen, Germany, 7Pediatric Rheumatology, Sankt Josef Stift Sendenhorst, Sendenhorst, Germany, 8Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, 9Pediatric Pain Centre,, Children's and Adolescents' Hospital Datteln, Datteln, Germany, 10Institute of Immunology, University of Muenster, Muenster, Germany

    Background/Purpose: The differential diagnosis of fever of unknown origin (FUO) is a major challenge in pediatrics especially for differentiation of systemic-onset juvenile idiopathic arthritis (SJIA)…
  • Abstract Number: 16 • 2017 Pediatric Rheumatology Symposium

    Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) Myositis Autoantibody Groups

    Hanna Kim1, Angélique Biancotto2, Foo Cheung3, Terrance P. O'Hanlon4, Ira N. Targoff5, Yan Huang6, Frederick Miller4, Raphaela Goldbach-Mansky6 and Lisa G. Rider4, 1Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, 2Center for Human Immunology, Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, 3Center for Human Immunology Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, 4Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 5VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Translational Autoinflammatory Disease Studies (TADS), NIAID, NIH, Bethesda, MD

    Background/Purpose: Juvenile dermatomyositis (JDM) is a complex heterogeneous autoimmune disease.  Myositis-specific autoantibodies (MSAs), present in up to 80% of JDM patients, help define distinct phenotypes…
  • Abstract Number: 123 • 2016 ACR/ARHP Annual Meeting

    A Panel of Urinary Biomarkers to Assess Renal Involvement in Latin American Patients with Systemic Lupus Erythematosus

    José A. Gómez-Puerta1,2, Blanca L Ortiz Reyes1, Tomás Urrego1, Adriana L Vanegas2,3, Carlos Horacio Muñoz3,4, Mauricio Restrepo2, Wilmer Rojas-Zuleta2, Sofia Arteaga2, Luis Alonso Gonzalez4 and Gloria Vásquez1,4, 1Grupo de Inmunología Celular e Inmunogenética, Universidad de Antioquia, Medellín, Colombia, 2Rheumatology Unit, Universidad de Antioquia, Medellín, Colombia, 3Hospital Universitario de San Vicente Fundación, Medellín, Colombia, 4Rheumatology Unit, Universidad de Antioquia, Medellin, Colombia

    Background/Purpose:  Some previous studies in Caucasian, Asian, and African-american patients have shown promising results for several urinary biomarkers in patients with lupus nephritis (LN). However,…
  • Abstract Number: 793 • 2016 ACR/ARHP Annual Meeting

    Multi-Parametric Model Development for Assessing Lupus Nephritis and Disease Activity

    Christopher Sjöwall1, Chelsea Bentow2, Mary Ann Aure2, Gabriella Lakos2, Peter Martis2 and Michael Mahler2, 1Rheumatology/AIR, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, 2Research and Development, Inova Diagnostics, San Diego, CA

    Multi-parametric model development for assessing lupus nephritis and disease activity Christopher Sjӧwall1, Chelsea Bentow2, Mary Ann Aure2, Gabriella Lakos2, Peter Martis2, Michael Mahler2 1AIR/Rheumatology, Department…
  • Abstract Number: 1380 • 2016 ACR/ARHP Annual Meeting

    Multicenter Prospective Study on the Role of Urinary HER2 As a Lupus Nephritis Biomarker

    Patrícia Costa Reis1, Kelly Maurer2, Emily von Scheven3, Kathleen O'Neil4, Jon M. Burnham5, Laura E. Schanberg6, Michelle Petri7 and Kathleen E. Sullivan8, 1Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, 3Division of Rheumatology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, 4Pediatrics, Indiana University, Indianapolis, IN, 5Pediatric Rheumatology, Children's Hospital Philadelphia, Philadelphia, PA, 6Pediatrics, Duke Medical Center, Durham, NC, 7Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, 8Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: HER2 (Human Epidermal Growth Factor Receptor 2) is dramatically overexpressed in the glomeruli and in the tubular compartment of patients with lupus nephritis, but…
  • Abstract Number: 2067 • 2016 ACR/ARHP Annual Meeting

    Dermal Fibroblasts from Patients with Lupus Nephritis Express an Anti-Fibrotic Transcriptome

    Robert M Clancy1, Evan Der2, Kemal Akat3, Anna R. Broder4, H. Michael Belmont5, Peter M. Izmirly5, Beatrice Goilav6, Thomas Tuschl3, Chaim Putterman6 and Jill P. Buyon7, 1Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 2Albert Einstein College of Medicine, Bronx, NY, 3Rockefeller University, New York, NY, 4Medicine/Rheumatology, Division of Rheumatology, Albert Einstein College of Med, Bronx, NY, 5New York University School of Medicine, New York, NY, 6Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, 7Medicine, New York University School of Medicine, New York, NY

    Background/Purpose: The premise of this study is that the impact of renal injury in lupus nephritis is widespread with consequences to resident cells in other…
  • « Previous Page
  • 1
  • …
  • 64
  • 65
  • 66
  • 67
  • 68
  • …
  • 96
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology